Boeing CFO Expects R&D To "Modestly Go Up" Over Next Few Years But Not Affect Cash Flow Goal; CEO Considers Spirit Remedy Unique, Adds That Rates Solve Most Supply Chain Problems
Portfolio Pulse from Benzinga Newsdesk
Boeing's CFO anticipates a modest increase in R&D expenditure over the next few years, but does not expect it to impact the company's cash flow goal. The CEO views the Spirit remedy as unique and believes that rates can solve most supply chain issues.
October 25, 2023 | 3:28 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Boeing's R&D costs are expected to rise modestly in the next few years, but this is not anticipated to affect the company's cash flow goal. The CEO's comments on the Spirit remedy and supply chain issues may also impact investor sentiment.
The news directly pertains to Boeing's financial outlook and operational strategies. While the increase in R&D costs could be seen as a negative, the assurance that it won't affect cash flow goals neutralizes this. The CEO's comments on supply chain issues could be seen as a positive, indicating management's confidence in handling these challenges.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEUTRAL IMPACT
Boeing's CEO's comments on the Spirit remedy being unique could potentially impact Spirit AeroSystems. However, the exact nature of this impact is unclear from the news.
The news mentions Spirit AeroSystems in relation to Boeing's CEO's comments. However, without further context or details on the 'Spirit remedy', it's difficult to determine the exact impact this will have on Spirit AeroSystems.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 50